Provided By GlobeNewswire
Last update: Jul 27, 2023
SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company’s second quarter 2023 financial results on Thursday, August 03, 2023, after the close of the U.S. financial markets.
NASDAQ:ALGS (12/19/2025, 8:27:51 PM)
10.68
+0.31 (+2.99%)
Find more stocks in the Stock Screener


